Tom joined Venrock as a Partner in 2017 and is currently an advisor to the firm as well as Chief Product Officer for Opendoor. Previously, he was Chief Product Officer at Coursera, where he helped to scale the company from $1 million to $100 million in revenue. He also led product teams at Netflix, where he helped to expand the company’s subscribership from 8 million U.S.-only users to over 40 million globally. Tom is a seasoned leader with deep experience building scalable products across multiple sectors.
Tony joined Venrock in 1974 and built the firm’s healthcare franchise, helping to shape the modern biotechnology industry. He currently serves on the Board of Directors of two public companies, AVEO Pharmaceuticals (NASDAQ: AVEO) and Infinity Pharmaceuticals (NASDAQ: INFI). Past investments include Acceleron (NASDAQ: XLRN), Celladon (NASDAQ: CLDN), Centocor (IPO/ acquired by Johnson & Johnson), Coley Pharmaceutical Group (IPO/ acquired by Pfizer), Genetics Institute (IPO/ acquired by Wyeth), Icagen (IPO/ acquired by Pfizer), IDEC Pharmaceuticals (IPO/ merged with Biogen), IDEXX Laboratories (NASDAQ: IDXX), Millennium Pharmaceuticals (IPO/acquired by Takeda) and Sepracor (IPO/acquired by Dainippon Sumitomo). More than 30 of his investments have been through an IPO during his Venrock tenure.
Tony started his career as a Research Scientist and Group Leader in Organic Chemistry at Union Carbide and as Director of Product Development at Story Chemical. He serves as a Trustee of The Jackson Laboratory, as a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center, as a Director of the New York Genome Center, as a Chairman of the Albert and Mary Lasker Foundation, and as a Trustee Emeritus of Princeton University and The Rockefeller University. Tony is focused on building valuable companies that address important medical needs of the world, while providing strong returns for investors.
Tony received his A.B. in Chemistry from Princeton University and his Ph.D. in Chemistry from the Massachusetts Institute of Technology.
Steve joined Venrock in 2007 after spending nine years as CEO of Venrock-backed materials science company Symyx Technologies. He serves on the Board of Directors of Nanosys and Phononic Devices. Previously, he served on the Boards of Affymax (acquired by GlaxoSmithKline), Aspect Development (acquired by i2 Technologies), Ilypsa (acquired by Amgen), Intermolecular, One Touch Systems (acquired by Apollo Group), PeopleSoft (acquired by Oracle), Scientific Software (acquired by Agilent), Scios (acquired by Johnson & Johnson), TGV (acquired by Cisco) and Vitae Pharmaceuticals.
Prior to Symyx, Steve served as the CEO of MDL Information Systems, a leading scientific information company, before its sale to Reed Elsevier. Prior to MDL, he held various management positions at Alza Corporation (acquired by Johnson and Johnson), including President of Alza Pharmaceuticals. Steve was also President of Dynapol, a specialty chemical company and is a registered patent attorney.
Steve earned an A.B. in Chemistry from the University of North Carolina and a J.D. from Georgetown University Law Center.